Whole Genome Sequencing for Blood Group Genotyping and Definition as Exemplified on U- and St(a)+.

Genetic Blood Group (bg) Polymorphism in U Negativity and St(a) of MNSs Clinical Trial

— Blood Genome  

Official title:

Applicability of Whole Genome Sequencing for Human Blood Group Genotyping and Genetic Definition of New Alleles as Exemplified on References and the Two MNSs-variants: U- and Stones(a)+

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02534519
• Other study ID #: KEK-ZH-Nr. 2014-0408
• Status: Recruiting
• Phase: N/A
• First received: August 10, 2015
• Last updated: August 24, 2015
• Start date: July 2015
• Est. completion date: June 2018

Study information

• Verified date: August 2015
• Source: Blood Donation Service Zurich, SRC
• Contact: Christoph Gassner, PhD
• Phone: +41 58 272 5195
• Email: c.gassner[@]zhbsd.ch
• Is FDA regulated: No
• Health authority: Switzerland: Cantonal Office of Public Health
• Study type: Observational [Patient Registry]

Clinical Trial Summary

No health condition(s) are studied. Genetic background of blood groups is studied. U- and Stones(a)+ ("Caucasian type") are used as proof-of-principle samples. Disease associations of all blood group genes investigated are very rare, e.g. < 1 among 1'000 Swiss individuals (see table 1), and are not to be expected in the course of this study.

Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent.

Description:

All 34 human blood group systems have at least two antithetical antigens and are of potential relevance during pregnancy and transfusion. Fortunately for every day routine practice, immunizations to foreign antigens are rare. Still, incompatibilities may occur in all blood group systems and will then require typing for the respective blood group antigens.

Blood genotyping evolved as the method of choice, in cases when typing reagents are commercially unavailable, or blood is inaccessible (foetus). In databases, most entries of blood group genes lack representative polymorphism (e.g. number of alleles). Moreover, many blood group antigens are insufficiently described in their intronic and inter-genetic sequences. This is true for results of unequal crossing-overs, gene-conversions and large insertions/deletions between highly homologous genes, especially within the blood group systems of Rhesus, e.g. RhD/RhCE and MN/Ss, respectively. Only Whole Genome Sequencing (WGS) allows for resolution of both problems: it delivers the whole blood group genome of an individual, and simultaneously recognizes new blood group alleles, or haplotypes. This request for ethical approval wants to test this assumption.

The antigenic determinants U- and Stones(a)+ of the blood group system MNSs still lack full genetic description and will serve as challenging examples for the description of new alleles (haplotypes) caused by large ins/del mutations of the two highly homologous genes GYPA and B. Genomic DNA of 2 U- samples were both provided as blinded reference material from New York and Vienna blood centres, respectively. Both donors are lost for follow up, and although there is no documented evidence for refusal of the respective donors to use their material in research projects, samples still lack informed consent. Additional reference samples (n max=4), and samples with suspected Stones(a)+ (n max=4) will be recruited from Zurich blood donors with informed consent, only.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: June 2018
• Est. primary completion date: June 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 1 Year to 70 Years

Eligibility

Inclusion Criteria:

• Existing biomaterial (gDNA), or

• Existing health related data for blood group U- (n max=2) and eligible for (venous) blood sampling of 20 mL, or

• Existing blood group pheno- and genotyping data indicating St(a)+ and eligible for (venous) blood sampling of 20 mL (n max=2), or

• Adequate blood group profile serving as reference (n max =4 & n max =4'000) and eligible for (venous) blood sampling of 20 mL.

Exclusion Criteria:

• Ineligible for venous blood sampling of approx. 20 mL.

Study Design

Observational Model: Case Control

Related Conditions & MeSH terms

• Genetic Blood Group (bg) Polymorphism in U Negativity and St(a) of MNSs

Intervention

Other:
• Whole Genome Sequencing (WGS)
There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.

Locations

Country	Name	City	State
Switzerland	Blutpende Zürich, Dienstleistungszentrum	Schlieren	Zürich

Sponsors (1)

Lead Sponsor	Collaborator
Blood Donation Service Zurich, SRC

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whole Genome Sequencing for the definition of genetic background for blood group antigens U-, St(a)+	During a 2 year time-period, whole genome sequencing data generation and analysis will be used for the analysis and description of the genetic background for the blood group antigens U negativity, and for St(a).	2 year period	No